Barclays analyst Geoff Meacham raised the price target on Regeneron Pharma (NASDAQ: REGN) to $315.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Regeneron Pharma (REGN) PT Raised to $396 at CitiNovember 7, 2018 7:17 AM Sanofi (SNY), Regeneron (REGN) Report FDA Priority Review Acceptance of Supplemental Biologics License Application for DupixentNovember 6, 2018 8:18 AM FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitisNovember 6, 2018 8:00 AM Regeneron (REGN) Tops Q3 EPS by 69c, Revenues BeatNovember 6, 2018 6:37 AM Regeneron Reports Third Quarter 2018 Financial and Operating ResultsNovember 6, 2018 6:30 AM FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitisNovember 6, 2018 1:02 AM FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitisNovember 6, 2018 1:01 AM FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic DermatitisNovember 6, 2018 12:59 AM